U.S. markets closed


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.9201+0.0001 (+0.01%)
At close: 04:00PM EDT
0.9200 -0.00 (-0.01%)
After hours: 04:00PM EDT
Sign in to post a message.
  • S
    Market Cap 39 million.
    As of Dec. 31, 2021, AVROBIO had $189.6 million in cash and cash equivalents.
    More than $3/share Net cash value.
  • T
    Clinical results are released this morning and the news is outstanding. Investor update on-line at 8am CT today.
  • T
    There will be no significant, sustained increase in share price until the Underwriters of the recent offering have unloaded their positions. AVRO got the cash, the Underwriters are making an outstanding gain, and the shareholders are left holding the bag. Same old story, follow the money.
  • T
    FDA guidance states drug developers cannot assume a surrogate endpoint used in the development of one therapy will be applicable to their programs

    If Avrobio wins approval under the new plan, it will receive a full authorization that spares it from the conditions the FDA imposes on products that come to market via the accelerated pathway.
  • J
    Jay X
    What is happening here? Any action?!
  • 💊C
    Morgan Stanley Conference presentation today.. someone is going to see this and know it is worth $16+ so keep it up!
  • T
    FDA getting slammed by several patients giving their perspective of the regulatory agency at the Gene and Cell Therapy sessions sponsored by the World Medical Innovation Forum.
  • T
    Dramatic drop in share price is in my opinion a direct result of the fear associated with dependence upon the FDA. Supposedly we will hear something in May about the March meeting that AVRO had with the FDA. Maybe AVRO can get approval for their technology from other countries and let the FDA deal with the fall out from families desperate for treatment options.
  • R
    How does gene therapy compare to protein therapeutics?
    It seems protein therapeutics is an forever treatment for the disease condition such as Gaucher.
    Is the gene therapy approach of $AVRO a one time injection of altered stem cells, and thus superior?

  • A
    Have you guys listened to the webcast?

    These results are nothing short of amazing.

    Check back at end of Q1, pps will be much higher.
  • C
    It appears (appearances are deceiving) that avro and fold are chasing some of the same diseases. Any smart folks care to share what the differences are their respective technologies?
    May it be that, to a certain extent, avro is trading in sympathy with fold for last 45 days?
  • g
    Learned a hard lesson. Never buy small biotech shares. They never have enough money because they always got robbed by hedgefunds when markets are low to compensate their losses.
  • J
    Jack Georges
    BLUE trials halt tanking AVRO with it. BLUE is determining how their patient contracted Leukemia 5 years after drug dosing. Wall Street is selling anything that uses the LentilViral gene therapy method
  • T
    Here is an update on the Bluebird Bio issue concerning the SUSAR:

    "Last month, the company reported that it is very unlikely the suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML) reported in the HGB-206 study of LentiGlobin for SCD was related to the BB305 lentiviral vector (LVV). This assessment, along with the re-classification of the originally reported MDS case to transfusion-dependent anemia are important steps in bluebird bio’s path to seeking removal of the clinical hold on studies HGB-206 and HGB-210 of LentiGlobin for SCD. bluebird bio continues to work with regulators to resume its clinical studies in sickle cell disease as well as to remove the clinical hold for HGB-207 and HGB-212 clinical studies of beti-cel for β-thalassemia, with potential lift of all clinical holds in mid-2021."
  • T
    I'll feel a lot better when the pundits stop telling the world how great AVRO is. Until they finish their selling, the glowing articles will continue to "pump and dump". Here are some comments from an article today.

    "there are 7 recent reviews on file for this biotech firm, and they break down 6 to 1 in favor of Buy over Hold, giving Avrobio its Strong Buy consensus rating"
  • R
    $NTLA conversation
    What did Gene Editing do- took away the sails of several Gene Therapy Drug Companies with Hudred M to over Billion dollar pipelines- Why? Ask this before you sell your stock at a lower price than what you bought for- taking profits is fine with me:

    2021 so far been quite bad year for trad gene tx..

    -from 52 week high (VYGR ADVM both -EV)

    $VYGR -72%
    $ADVM -85%
    $QURE -43%
    $BLUE -54%
    $avro -57%
    $PASG -56%
    $GBIO -53%
    $SRPT -59%
  • T
    Not in our lifetime! That is my take away from reading FDA comments about gene therapy. Does anyone really think that gene editing will be any less scrutinized.

    Following is a paragraph from and article written by Annalee Armstrong and Kyle LaHucik for Fierce Biotech

    But despite the promise in these gene therapies, the FDA has flagged safety concerns ranging from liver toxicity to kidney injury to a loss of neurons. These issues have long been noted as gene therapies moved toward market and patients died during earlier clinical trials.
  • s
    Looks like end of selling based on volume and price movement. What great stock for MMs (Market Manipulators) to milk retail investors (that means you mom & pop investors)...

    After 6 weeks of selling above normal average we are coming down...

    Buy some here at 1.5 and wait a year. This reminds me of AM two years ago where it was knocjked down below 2 and now it trades around 10...

    So cheap compare to cash level and 4-5 drugs in the pipeline...

    Still has to consider cash burn rate and should be enough for mid 2024...

    Good Luck to all and do your due diligence always...
  • T
    One week from today we start getting investigational study results. Be sure to listen to the AVROBIO Virtual Investor Event at the 17th Annual WORLDSymposium™ 2021.
    Feb 8, 2021 from 8:00 AM to 9:30 AM EST
  • Y
    Yahoo Finance Insights
    AVROBIO reached a 52 Week low at 0.80